Cargando…

Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma

BACKGROUND: Effective prognostic biomarkers and powerful target-therapeutic drugs are needed for improving the treatment of Hepatocellular carcinoma (HCC). OBJECTIVE: This study aimed to evaluate the expression of FOXM1 and Aurora-A and their prognostic value in HCC. METHODS: We determined the diffe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Wen-Lung, Chuang, Shih-Chang, Wang, Yu-Chu, Chen, Lin-An, Huang, Jian-Wei, Chang, Wen-Tsan, Wang, Shen-Nien, Lee, King-Teh, Lin, Chang-Shen, Kuo, Kung-Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458516/ https://www.ncbi.nlm.nih.gov/pubmed/32390596 http://dx.doi.org/10.3233/CBM-190507

Ejemplares similares

FOXM1-Mediated LINC-ROR Regulates the Proliferation and Sensitivity to Sorafenib in Hepatocellular Carcinoma
por: Zhi, Yingru, et al.
Publicado: (2019)

FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer Cells
por: Wuputra, Kenly, et al.
Publicado: (2022)

Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple‐negative breast cancer
por: Yang, Na, et al.
Publicado: (2019)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC
por: Lin, Zhong-Zhe, et al.
Publicado: (2010)

Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
por: Chu, Shou-Sheng, et al.
Publicado: (2021)

A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma
por: Song, Bic-Na, et al.
Publicado: (2018)

Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism
por: Shueng, Pei-Wei, et al.
Publicado: (2022)

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Liao, Li-Zhu, et al.
Publicado: (2020)

The Potential Interplay of Adipokines with Toll-Like Receptors in the Development of Hepatocellular Carcinoma
por: Wang, Shen-Nien, et al.
Publicado: (2011)

A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma
por: Zhang, Kai, et al.
Publicado: (2018)

Beneficial Effect of Combining Radiotherapy and Transarterial Chemoembolization on Patient Survival in Hepatocellular Carcinomas and Macrovascular Invasion Treated with Sorafenib
por: Lu, Meng-Chuan, et al.
Publicado: (2023)

Impact of bromodomain‐containing protein 4 (BRD4) and intestine‐specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity
por: Chuang, Kai‐Ting, et al.
Publicado: (2021)

Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma
por: Liang, Kung-Hao, et al.
Publicado: (2021)

Translational upregulation of Aurora-A by hnRNP Q1 contributes to cell proliferation and tumorigenesis in colorectal cancer
por: Lai, Chien-Hsien, et al.
Publicado: (2017)

Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma
por: Fan, Weiqiang, et al.
Publicado: (2022)

circFOXM1 contributes to sorafenib resistance of hepatocellular carcinoma cells by regulating MECP2 via miR-1324
por: Weng, Hanqin, et al.
Publicado: (2021)

Overexpression of Aurora-C interferes with the spindle checkpoint by promoting the degradation of Aurora-B
por: Lin, B-W, et al.
Publicado: (2014)

Sorafenib induces autophagy and suppresses activation of human macrophage
por: Lin, Jiunn-Chang, et al.
Publicado: (2013)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy
por: Shao, Mingyang, et al.
Publicado: (2023)

Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma
por: Sun, Hong, et al.
Publicado: (2022)

Translational up-regulation of Aurora-A in EGFR-overexpressed cancer
por: Lai, Chien-Hsien, et al.
Publicado: (2010)

Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma
por: Ho, Chun-Ming, et al.
Publicado: (2022)

Progesterone Increases Apoptosis and Inversely Decreases Autophagy in Human Hepatoma HA22T/VGH Cells Treated with Epirubicin
por: Chang, Wen-Tsan, et al.
Publicado: (2014)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

From imaging to clinical outcome: dual-region CT radiomics predicting FOXM1 expression and prognosis in hepatocellular carcinoma
por: Chen, Xianyu, et al.
Publicado: (2023)

Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
por: Pan, Yu, et al.
Publicado: (2021)

Overexpression of FoxM1 predicts poor prognosis of intrahepatic cholangiocarcinoma
por: Liu, Lingyun, et al.
Publicado: (2018)

FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells
por: Yang, N, et al.
Publicado: (2017)

Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study
por: Teng, Chieh-Lin, et al.
Publicado: (2012)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer
por: Chen, Chang-Han, et al.
Publicado: (2015)

Cryotherapy is Associated with Improved Clinical Outcomes of Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Yang, Yongping, et al.
Publicado: (2012)

Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma
por: Hsiao, Pojen, et al.
Publicado: (2019)

Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study
por: Kok, Victor C., et al.
Publicado: (2019)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells
por: Lin, Jiunn-Chang, et al.
Publicado: (2021)

Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study
por: Hsiao, Wang-De, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jk2ej36ckdvbicoirilep8p5q8